Advertisement

Analytical and Bioanalytical Chemistry

, Volume 388, Issue 5–6, pp 1147–1156 | Cite as

Determination of drug–serum protein interactions via fluorescence polarization measurements

  • Ulf Mathias
  • Manfred Jung
Original Paper

Abstract

New fast methods for the determination of pharmacokinetic behaviour of potential drug candidates are receiving increasing interest. We present a new homogeneous method for the determination of drug binding and drug competition for human serum albumin and α1-acid glycoprotein that is amenable to high-throughput-screening. It is based on selective fluorescent probes and the measurement of fluorescence polarization. This leads to decreased interference with fluorescent drugs as compared with previously published methods based on similar probes and the measurement of fluorescence intensity. The binding of highly fluorescent drugs that still interfere with the probes can be measured by simply titrating the drugs in a two-component system with the serum protein. The assay may also be used to discover strongly binding protein ligands that are interesting for drug-targeting strategies. Additionally, binding data could be obtained from larger libraries of compounds for in silico predictive pharmacokinetics.

Figure

Fluorescence polarization displacement titration of dansylsarcosine (3D-structure as insert) bound to human serum albumin (HSA) by naproxene

Keywords

Human serum albumin α1-acid glycoprotein High-throughput-screening Early-ADME tests Fluorescence polarization 

Notes

Acknowledgements

We thank Roche Diagnostics (Penzberg, Germany) for financial support, L. Stecher and S. Wittich for exploratory experiments and W. Sippl (Halle) for the 3D graphic for the online edition.

Supplementary material

References

  1. 1.
    Eddershaw PJ, Beresford AP, Bayliss MK (2000) Drug Discov Today 5:409–414CrossRefGoogle Scholar
  2. 2.
    van de Waterbeemd H (2002) Curr Opin Drug Discov Dev 5:33–43Google Scholar
  3. 3.
    Fasano M, Curry S, Terreno E, Galliano M, Fanali G, Narciso P, Notari S, Ascenzi P (2005) IUBMB Life 57:787–796Google Scholar
  4. 4.
    Carter DC, Ho JX (1994) Adv Protein Chem 45:153–203CrossRefGoogle Scholar
  5. 5.
    Solomon HM, Schrogie JJ, Williams D (1968) Biochem Pharmacol 17:143–151CrossRefGoogle Scholar
  6. 6.
    Kaliszan R (1998) J Chromatogr B 715:229–244CrossRefGoogle Scholar
  7. 7.
    Colmenarejo G, Alvarez-Pedraglio A, Lavandera JL (2001) J Med Chem 44:4370–4378CrossRefGoogle Scholar
  8. 8.
    Epps DE, Raub TJ, Kezdy FJ (1995) Anal Biochem 227:342–350CrossRefGoogle Scholar
  9. 9.
    Frostell-Karlsson A, Remaeus A, Roos H, Andersson K, Borg P, Hamalainen M, Karlsson R (2000) J Med Chem 43:1986–1992CrossRefGoogle Scholar
  10. 10.
    Rich RL, Day YS, Morton TA, Myszka DG (2001) Anal Biochem 296:197–207CrossRefGoogle Scholar
  11. 11.
    Epps DE, Raub TJ, Caiolfa V, Chiari A, Zamai M (1999) J Pharm Pharmacol 51:41–48CrossRefGoogle Scholar
  12. 12.
    Parikh HH, McElwain K, Balasubramanian V, Leung W, Wong D, Morris ME, Ramanathan M (2000) Pharm Res 17:632–637CrossRefGoogle Scholar
  13. 13.
    Jameson DM, Croney JC (2003) Comb Chem High Throughput Screen 6:167–173Google Scholar
  14. 14.
    Owicki JC (2000) J Biomol Screen 5:297–306CrossRefGoogle Scholar
  15. 15.
    Sportsman JR, Daijo J, Gaudet EA (2003) Comb Chem High Throughput Screen 6:195–200Google Scholar
  16. 16.
    Burke TJ, Loniello KR, Beebe JA, Ervin KM (2003) Comb Chem High Throughput Screen 6:183–194Google Scholar
  17. 17.
    de Jong LA, Uges DR, Franke JP, Bischoff R (2005) J Chromatogr B 829:1–25CrossRefGoogle Scholar
  18. 18.
    Saldanha SA, Kaler G, Cottam HB, Abagyan R, Taylor SS (2006) Anal Chem 78:8265–8272CrossRefGoogle Scholar
  19. 19.
    Hu Y, Helm JS, Chen L, Ginsberg C, Gross B, Kraybill B, Tiyanont K, Fang X, Wu T, Walker S (2004) Chem Biol 11:703–711CrossRefGoogle Scholar
  20. 20.
    Antczak C, Shum D, Escobar S, Bassit B, Kim E, Seshan VE, Wu N, Yang G, Ouerfelli O, Li YM, Scheinberg DA, Djaballah H (2007) J Biomol Screen (in press)Google Scholar
  21. 21.
    Klumpp M, Boettcher A, Becker D, Meder G, Blank J, Leder L, Forstner M, Ottl J, Mayr LM (2006) J Biomol Screen 11:617–633CrossRefGoogle Scholar
  22. 22.
    Moreno F, Gonzalez-Jimenez J (1999) Chem Biol Interact 121:237–252CrossRefGoogle Scholar
  23. 23.
    Moreno F, Cortijo M, Gonzalez-Jimenez J (1999) Photochem Photobiol 69:8–15CrossRefGoogle Scholar
  24. 24.
    Sudlow G, Birkett DJ, Wade DN (1976) Mol Pharmacol 12:1052–1061Google Scholar
  25. 25.
    Sudlow G, Birkett DJ, Wade DN (1975) Mol Pharmacol 11:824–832Google Scholar
  26. 26.
    Israili ZH, Dayton PG (2001) Drug Metab Rev 33:161–235CrossRefGoogle Scholar
  27. 27.
    Maruyama T, Otagiri M, Takadate A (1990) Chem Pharm Bull 38:1688–1691Google Scholar
  28. 28.
    Cheng Y, Prusoff WH (1973) Biochem Pharmacol 22:3099–3108CrossRefGoogle Scholar
  29. 29.
    Kenakin TP (1993) In: Pharmacologic analysis of drug/receptor interaction, 2nd edn. Raven, New York, pp 385–410Google Scholar
  30. 30.
    Swillens S (1995) Mol Pharmacol 47:1197–1203Google Scholar
  31. 31.
    Munson PJ, Rodbard D (1988) J Recept Res 8:533–546; Erratum 1989-1990, 1989, 1511Google Scholar
  32. 32.
    Kratochwil NA, Huber W, Muller F, Kansy M, Gerber PR (2002) Biochem Pharmacol 64:1355–1374CrossRefGoogle Scholar
  33. 33.
    Kopitar Z, Weisenberger H (1971) Arzneim Forsch 21:859–862Google Scholar
  34. 34.
    Hartung G, Stehle G, Sinn H, Wunder A, Schrenk HH, Heeger S, Kranzle M, Edler L, Frei E, Fiebig HH, Heene DL, Maier-Borst W, Queisser W (1999) Clin Cancer Res 5:753–759Google Scholar
  35. 35.
    Kratz F, Muller-Driver R, Hofmann I, Drevs J, Unger C (2000) J Med Chem 43:1253–1256CrossRefGoogle Scholar
  36. 36.
    Warnecke A, Kratz F (2003) Bioconjug Chem 14:377–387CrossRefGoogle Scholar
  37. 37.
    Votano JR, Parham M, Hall LM, Hall LH, Kier LB, Oloff S, Tropsha A (2006) J Med Chem 49:7169–7181CrossRefGoogle Scholar
  38. 38.
    Zhang JH, Chung TD, Oldenburg KR (1999) J Biomol Screen 4:67–73CrossRefGoogle Scholar
  39. 39.
    Piafsky KM, Borga O (1977) Clin Pharmacol Ther 22:545–549Google Scholar
  40. 40.
    Brinkschulte M, Breyer-Pfaff U (1980) Naunyn Schmiedebergs Arch Pharmacol 314:61–66CrossRefGoogle Scholar
  41. 41.
    Kornguth ML, Hutchins LG, Eichelmann BS (1981) Biochem Pharmacol 30:2345–2441CrossRefGoogle Scholar
  42. 42.
    Israili ZH, El-Attar H (1983) Clin Pharmacol Ther 33:255Google Scholar
  43. 43.
    Israili ZH, Bharmal F, Tiliakos N (1985) Fed Proc 44:1124Google Scholar
  44. 44.
    Brunner F, Muller WE (1987) J Pharm Pharmacol 39:986–990Google Scholar
  45. 45.
    McGowan FX, Reiter MJ, Pritchett EL, Shand DG (1983) Clin Pharmacol Ther 33:485–490CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Institute of Pharmaceutical SciencesUniversity of FreiburgFreiburgGermany

Personalised recommendations